Public Market Listing
4568 TSE
TSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (21 total) 21 Total Assets
10 Approved
6 Phase 3 / Filed
5 Phase 1–2 / Early
25 Diseases
Disease: All diseases (21) Non-Small Cell Lung Cancer (11) Breast Cancer (4) Atherosclerotic Cardiovascular Disease (2) Chronic Kidney Disease (2) Cervical Cancer (1) Colorectal Cancer (1) Renal Cell Carcinoma (1) Glioblastoma (1) Type 2 Diabetes (1) Bladder / Urothelial Cancer (1) Rheumatoid Arthritis (1) Osteoporosis (1) Heart Failure (1) Iron Deficiency Anemia (1) Migraine (1) Acute Myeloid Leukemia (1) Multiple Myeloma (1) Hypertension (1) Metastatic Castration-Resistant Prostate Cancer (1) Small Cell Lung Cancer (1) Esophageal Cancer (1) Diabetic Peripheral Neuropathic Pain (1) Ovarian Cancer (1) Non-Hodgkin Lymphoma (1) Systemic Lupus Erythematosus (1)
Stage: All stages (21) Approved / Phase 4 (10) Phase 3 / Filed (6) Phase 2 Phase 1 / Preclinical
Quick filter: All (21) Non-Small Cell Lung Cancer (11) Breast Cancer (4) Atherosclerotic Cardiovascular Disease (2) Chronic Kidney Disease (2) Cervical Cancer (1)
Showing 21 of 21 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved ATP citrate lyase Small molecule
Atherosclerotic Cardiovascular Disease
Approved ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) Small molecule
Atherosclerotic Cardiovascular Disease
Approved VEGF-A Monoclonal antibody
Non-Small Cell Lung Cancer Cervical Cancer Colorectal Cancer Renal Cell Carcinoma Glioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer Approved SGLT2 Small molecule
Type 2 Diabetes Chronic Kidney Disease
Approved TROP2 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer Bladder / Urothelial Cancer
HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma Approved RANKL Monoclonal antibody
Rheumatoid Arthritis Osteoporosis
Approved Iron repletion Other
Heart Failure Chronic Kidney Disease Iron Deficiency Anemia
Approved CGRP ligand Monoclonal antibody
Approved FLT3 Small molecule
Approved HER2 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer Phase 3 RANKL Monoclonal antibody
Non-Small Cell Lung Cancer Multiple Myeloma Breast Cancer
HR+/HER2- Metastatic Breast Cancer Phase 3 Mineralocorticoid receptor Small molecule
Phase 3 B7-H3 Antibody–drug conjugate
Non-Small Cell Lung Cancer Metastatic Castration-Resistant Prostate Cancer Small Cell Lung Cancer Esophageal Cancer
Esophageal Squamous Cell Carcinoma Phase 3 α2δ-1 subunit of voltage-gated calcium channels Small molecule
Diabetic Peripheral Neuropathic Pain
Phase 3 HER3 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Show all 21 assets (6 more) ↓ Discontinued programmes (1) Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events (76 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (16) January 2027 (1) February 2027 (1) Trastuzumab Deruxtecan Phase 2 Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) Est. primary completion 2027-02-10 ·
NCT06271837 ·
CT.gov ↗ What to watch
March 2027 (1) Trastuzumab Deruxtecan Phase 2 Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric … Est. primary completion 2027-03-23 ·
NCT04482309 ·
CT.gov ↗ What to watch
April 2027 (1) Ifinatamab Deruxtecan Phase 1/2 Advanced Solid Tumor, Malignant Solid Tumor Est. primary completion 2027-04-30 ·
NCT04145622 ·
CT.gov ↗ What to watch
May 2027 (4) Quizartinib Phase 1/2 Acute Myeloid Leukemia Est. primary completion 2027-05-01 ·
NCT03793478 ·
CT.gov ↗ What to watch
Est. primary completion 2027-05-04 ·
NCT04379596 ·
CT.gov ↗ What to watch
June 2027 (1) July 2027 (2) Est. primary completion 2027-07-28 ·
NCT06103864 ·
CT.gov ↗ What to watch
September 2027 (1) Est. primary completion 2027-09-01 ·
NCT05629585 ·
CT.gov ↗ What to watch
October 2027 (2) Datopotamab Deruxtecan Phase 2 Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer … Est. primary completion 2027-10-01 ·
NCT05489211 ·
CT.gov ↗ What to watch
Est. primary completion 2027-10-01 ·
NCT05950945 ·
CT.gov ↗ What to watch
November 2027 (2) Est. primary completion 2027-11-01 ·
NCT05687266 ·
CT.gov ↗ What to watch
2028 (21) January 2028 (2) Ifinatamab Deruxtecan Phase 1/2 Small-Cell Lung Cancer, Neuroendocrine Carcinoma Est. primary completion 2028-01-28 ·
NCT04471727 ·
CT.gov ↗ What to watch
February 2028 (4) Est. primary completion 2028-02-02 ·
NCT07205822 ·
CT.gov ↗ What to watch
Est. primary completion 2028-02-07 ·
NCT05417594 ·
CT.gov ↗ What to watch
Est. primary completion 2028-02-29 ·
NCT06161025 ·
CT.gov ↗ What to watch
March 2028 (2) May 2028 (1) Patritumab Deruxtecan Phase 1/2 Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer Est. primary completion 2028-05-09 ·
NCT06445972 ·
CT.gov ↗ What to watch
June 2028 (5) Quizartinib Phase 2 Acute Myeloid Leukemia, Leukemia Est. primary completion 2028-06-06 ·
NCT06824168 ·
CT.gov ↗ What to watch
July 2028 (1) August 2028 (1) DS-3939a Phase 1/2 Advanced Solid Tumor, Metastatic Solid Tumor Est. primary completion 2028-08-11 ·
NCT05875168 ·
CT.gov ↗ What to watch
November 2028 (2) Est. primary completion 2028-11-01 ·
NCT06819007 ·
CT.gov ↗ What to watch
Est. primary completion 2028-11-20 ·
NCT06112379 ·
CT.gov ↗ What to watch
December 2028 (3) 2029 (16) January 2029 (2) February 2029 (1) March 2029 (1) April 2029 (2) Trastuzumab Deruxtecan Phase 3 HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Est. primary completion 2029-04-27 ·
NCT06764875 ·
CT.gov ↗ What to watch
May 2029 (1) June 2029 (1) July 2029 (1) Raludotatug Deruxtecan Phase 3 Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian Est. primary completion 2029-07-01 ·
NCT07791732 ·
CT.gov ↗ What to watch
August 2029 (1) September 2029 (2) Patritumab Deruxtecan Phase 1/2 Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer Est. primary completion 2029-09-12 ·
NCT06469944 ·
CT.gov ↗ What to watch
December 2029 (4) 2030 (11) February 2030 (1) March 2030 (1) April 2030 (1) May 2030 (1) June 2030 (1) Quizartinib Phase 3 Leukemia Est. primary completion 2030-06-26 ·
NCT06578247 ·
CT.gov ↗ What to watch
July 2030 (2) Trastuzumab Deruxtecan Phase 3 Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive Est. primary completion 2030-07-04 ·
NCT07683754 ·
CT.gov ↗ What to watch
DS-3939a + DS-1103a Phase 1/2 Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer Est. primary completion 2030-07-31 ·
NCT07739966 ·
CT.gov ↗ What to watch
September 2030 (1) November 2030 (2) Patritumab Deruxtecan Phase 2 Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer … Est. primary completion 2030-11-19 ·
NCT06172478 ·
CT.gov ↗ What to watch
December 2030 (1) 2031 (4) January 2031 (1) Patritumab Deruxtecan Phase 1/2 Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer Est. primary completion 2031-01-01 ·
NCT07701941 ·
CT.gov ↗ What to watch
August 2031 (2) Raludotatug Deruxtecan Phase 3 Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Est. primary completion 2031-08-31 ·
NCT07743164 ·
CT.gov ↗ What to watch
October 2031 (1) Ifinatamab Deruxtecan Phase 1/2 Castration-Resistant Prostatic Cancer, Metastasis Est. primary completion 2031-10-01 ·
NCT06863272 ·
CT.gov ↗ What to watch
2032 (7) January 2032 (1) February 2032 (1) March 2032 (4) Est. primary completion 2032-03-02 ·
NCT06780098 ·
CT.gov ↗ What to watch
Est. primary completion 2032-03-12 ·
NCT06780085 ·
CT.gov ↗ What to watch
Raludotatug Deruxtecan Phase 3 Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer Est. primary completion 2032-03-19 ·
NCT07776691 ·
CT.gov ↗ What to watch
August 2032 (1) 2033 (1) See the full readout calendar ↗
Regulatory and conference events (12) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
27 October 2026 Approval Trastuzumab Deruxtecan EU approves Enhertu as adjuvant monotherapy in HER2-positive early breast cancer 25 September 2026 Withdrawal Ifinatamab Deruxtecan US BLA for ifinatamab deruxtecan in pretreated ES-SCLC voluntarily withdrawn 14 September 2026 Topline result Trastuzumab Deruxtecan DESTINY-Lung04: Enhertu met its PFS primary endpoint vs pembrolizumab plus chemotherapy 1 September 2026 Approval Trastuzumab Deruxtecan Enhertu with pertuzumab approved in the EU for first-line HER2-positive metastatic breast cancer 5 August 2026 Withdrawal Lasmiditan (Reyvow) FDA withdraws approval of NDA 211280 (Federal Register 2026-13616) 31 July 2026 Approval Datopotamab Deruxtecan Datroway approved in the EU for first-line metastatic TNBC in patients who are not candidates for immunotherapy 7 September 2025 Topline result Ifinatamab Deruxtecan IDeate-Lung01 (NCT05280470) Phase 2: confirmed objective response rate 48.2% in 137 previously treated ES-SCLC patients 29 May 2025 Withdrawal Patritumab Deruxtecan US BLA for patritumab deruxtecan in EGFR-mutated NSCLC voluntarily withdrawn US, FDA · Daiichi Sankyo and Merck & Co. ·
Source ↗ 26 June 2024 Complete response letter Patritumab Deruxtecan FDA complete response letter for the patritumab deruxtecan BLA (third-party manufacturing inspection) US, FDA · Daiichi Sankyo and Merck & Co. ·
Source ↗ Financial reports Annual history (4 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-FY $14.0B $3.0B $3.1B — report ↗
View 3 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $12.4B $2.8B $4.3B — report ↗ 2023-FY $9.4B $2.5B $3.3B — report ↗ 2022-FY $9.3B $2.3B $5.4B — report ↗